IL297225A - Activatable cytokine constructs and related compositions and methods - Google Patents
Activatable cytokine constructs and related compositions and methodsInfo
- Publication number
- IL297225A IL297225A IL297225A IL29722522A IL297225A IL 297225 A IL297225 A IL 297225A IL 297225 A IL297225 A IL 297225A IL 29722522 A IL29722522 A IL 29722522A IL 297225 A IL297225 A IL 297225A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- acc
- amino acids
- cpi
- interferon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008542P | 2020-04-10 | 2020-04-10 | |
| US202163161889P | 2021-03-16 | 2021-03-16 | |
| US202163164849P | 2021-03-23 | 2021-03-23 | |
| PCT/US2021/026675 WO2021207669A1 (en) | 2020-04-10 | 2021-04-09 | Activatable cytokine constructs and related compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297225A true IL297225A (en) | 2022-12-01 |
Family
ID=75747127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297225A IL297225A (en) | 2020-04-10 | 2021-04-09 | Activatable cytokine constructs and related compositions and methods |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11365233B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4133085A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023520922A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220167295A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115667523B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021254283B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020440A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174786A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297225A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012592A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021207669A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| KR20230157448A (ko) * | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| WO2023034825A1 (en) | 2021-08-30 | 2023-03-09 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| WO2023060156A2 (en) * | 2021-10-08 | 2023-04-13 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| EP4486758A2 (en) * | 2022-03-03 | 2025-01-08 | The Trustees of the University of Pennsylvania | Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidism |
| EP4496816A1 (en) | 2022-03-23 | 2025-01-29 | CytomX Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス,インク. | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Cytomx生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| US20260015425A1 (en) | 2022-08-01 | 2026-01-15 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス,インク. | プロテアーゼ切断性部分及びその使用方法 |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130077A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| US20240067691A1 (en) * | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| CN120958015A (zh) | 2023-04-12 | 2025-11-14 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| EP4694934A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| CZ2003214A3 (cs) | 2000-06-29 | 2003-08-13 | Merck Patent Gmbh | Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| JP4334866B2 (ja) | 2000-10-09 | 2009-09-30 | アイシス イノヴェイション リミテッド | 治療用抗体 |
| GB0100551D0 (en) * | 2001-01-09 | 2001-02-21 | Queen Mary & Westfield College | Protein |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| US20060024272A1 (en) | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| CN101184771A (zh) * | 2005-05-26 | 2008-05-21 | 先灵公司 | 干扰素-IgG融合体 |
| EP1993608A1 (en) | 2006-03-10 | 2008-11-26 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| WO2009079837A1 (en) | 2007-12-18 | 2009-07-02 | Hangzhou Jiuyuan Gene Engineering Co., Ltd. | A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| US8734774B2 (en) | 2010-04-02 | 2014-05-27 | University Of Rochester | Protease activated cytokines |
| HRP20150664T1 (hr) | 2010-12-03 | 2015-07-31 | Adamed Sp. Z O.O. | Antikancerogeni fuzijski protein |
| CA2824515C (en) | 2011-01-18 | 2022-09-13 | Bioniz, Llc | Compositions and methods for modulating gamma-c-cytokine activity |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CN104363919A (zh) * | 2012-06-01 | 2015-02-18 | Ibc药品公司 | 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物 |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| GB201411506D0 (en) * | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
| PT3215528T (pt) | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| US20190216898A1 (en) | 2016-05-06 | 2019-07-18 | Wang Mulin | Interleukin Combination and Use Thereof |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| JP2020528878A (ja) | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| US12564632B2 (en) | 2017-11-08 | 2026-03-03 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| CN111954680B (zh) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| JP7386161B2 (ja) | 2017-12-19 | 2023-11-24 | ブレイズ バイオサイエンス, インコーポレイテッド | 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法 |
| WO2020113403A1 (en) | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| CA3115461A1 (en) | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| EP3816182A4 (en) | 2018-05-30 | 2022-07-13 | Chugai Seiyaku Kabushiki Kaisha | LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY |
| CN112351946B (zh) | 2018-06-21 | 2022-07-08 | Tgw物流集团有限公司 | 货仓及拣选系统和用于从悬挂袋和其他装载辅助器具中拣选订单货物的方法 |
| MX2020014290A (es) | 2018-06-22 | 2021-08-05 | Cugene Inc | Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| WO2020041758A1 (en) | 2018-08-24 | 2020-02-27 | City Of Hope | Masked cytokine conjugates |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| CA3114179A1 (en) | 2018-09-28 | 2020-04-02 | Pierre Fabre Medicament | New immunocytokines for the treatment of cancer |
| KR20210080460A (ko) | 2018-10-23 | 2021-06-30 | 드래곤플라이 쎄라퓨틱스, 인크. | 이종이량체성 Fc-융합된 단백질 |
| JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス,インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
| WO2020123980A1 (en) | 2018-12-14 | 2020-06-18 | Proviva Therapeutics (Hong Kong) Limited | Il-15 compositions and methods of use thereof |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| AU2020285636A1 (en) | 2019-05-24 | 2021-11-04 | Proviva Therapeutics (Hong Kong) Limited | IL-2 compositions and methods of use thereof |
| EP3981428A4 (en) | 2019-06-05 | 2023-07-12 | Chugai Seiyaku Kabushiki Kaisha | Protease substrate, and polypeptide including protease cleavage sequence |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| KR20260089650A (ko) | 2019-07-12 | 2026-06-15 | 프로비바 테라퓨틱스 (홍콩) 리미티드 | Il-2 조성물 및 이의 사용 방법 |
| AU2020316002B2 (en) | 2019-07-25 | 2026-05-07 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
| EP4004026A4 (en) | 2019-07-25 | 2023-11-15 | Trutino Biosciences Inc. | IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER |
| EP4013775A1 (en) | 2019-08-12 | 2022-06-22 | Askgene Pharma, Inc. | Il-2 fusion proteins that preferentially bind il-2ralpha |
| EP4017594A1 (en) | 2019-08-21 | 2022-06-29 | Askgene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| WO2021062406A1 (en) | 2019-09-28 | 2021-04-01 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| WO2021113577A1 (en) | 2019-12-05 | 2021-06-10 | Immune Targeting Inc. | Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof |
| AU2020403148A1 (en) * | 2019-12-13 | 2022-06-30 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| US20240043489A1 (en) | 2020-01-15 | 2024-02-08 | Trutino Biosciences Inc. | Cytokine Prodrugs Comprising a Cleavable Linker |
| MX2022011676A (es) | 2020-03-23 | 2023-03-08 | Zymeworks Bc Inc | Proteinas de fusion de il12 con enmascaramiento y metodos para su uso. |
| US20230226202A1 (en) | 2020-03-30 | 2023-07-20 | Proviva Therapeutics (Hong Kong) Limited | Il-2/il15 compositions and methods of use thereof |
| PH12022552630A1 (en) | 2020-04-01 | 2023-01-04 | Xilio Dev Inc | Masked il-15 cytokines and their cleavage products |
| BR112022019708A2 (pt) | 2020-04-01 | 2022-12-20 | Xilio Dev Inc | Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer |
| PH12022552627A1 (en) | 2020-04-01 | 2023-01-04 | Xilio Dev Inc | Masked il-2 cytokines and their cleavage products |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| CN115996946A (zh) | 2020-04-30 | 2023-04-21 | 免疫靶向有限公司 | 可活化il2组合物和使用方法 |
| CA3178657A1 (en) | 2020-05-19 | 2021-11-25 | William Winston | Activatable il-12 polypeptides and methods of use thereof |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| CN120958015A (zh) * | 2023-04-12 | 2025-11-14 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
-
2021
- 2021-04-09 AU AU2021254283A patent/AU2021254283B2/en active Active
- 2021-04-09 WO PCT/US2021/026675 patent/WO2021207669A1/en not_active Ceased
- 2021-04-09 JP JP2022561460A patent/JP2023520922A/ja active Pending
- 2021-04-09 MX MX2022012592A patent/MX2022012592A/es unknown
- 2021-04-09 US US17/227,017 patent/US11365233B2/en active Active
- 2021-04-09 KR KR1020227037537A patent/KR20220167295A/ko active Pending
- 2021-04-09 CN CN202180030934.8A patent/CN115667523B/zh active Active
- 2021-04-09 CA CA3174786A patent/CA3174786A1/en active Pending
- 2021-04-09 IL IL297225A patent/IL297225A/en unknown
- 2021-04-09 EP EP21722711.5A patent/EP4133085A1/en active Pending
- 2021-04-09 BR BR112022020440A patent/BR112022020440A2/pt unknown
- 2021-04-09 CN CN202610310636.9A patent/CN122060080A/zh active Pending
-
2022
- 2022-05-25 US US17/824,294 patent/US12091442B2/en active Active
-
2024
- 2024-08-15 US US18/806,635 patent/US20250179141A1/en active Pending
-
2026
- 2026-01-12 AU AU2026200173A patent/AU2026200173A1/en active Pending
- 2026-02-13 JP JP2026022244A patent/JP2026086743A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021254283A1 (en) | 2022-11-10 |
| US20210317177A1 (en) | 2021-10-14 |
| BR112022020440A2 (pt) | 2022-12-27 |
| EP4133085A1 (en) | 2023-02-15 |
| US20250179141A1 (en) | 2025-06-05 |
| CN115667523B (zh) | 2026-03-31 |
| US11365233B2 (en) | 2022-06-21 |
| CA3174786A1 (en) | 2021-10-14 |
| CN122060080A (zh) | 2026-05-19 |
| US20220402990A1 (en) | 2022-12-22 |
| US12091442B2 (en) | 2024-09-17 |
| MX2022012592A (es) | 2022-12-07 |
| AU2026200173A1 (en) | 2026-02-05 |
| JP2026086743A (ja) | 2026-05-26 |
| AU2021254283B2 (en) | 2025-12-11 |
| JP2023520922A (ja) | 2023-05-22 |
| KR20220167295A (ko) | 2022-12-20 |
| WO2021207669A1 (en) | 2021-10-14 |
| CN115667523A (zh) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021254283B2 (en) | Activatable cytokine constructs and related compositions and methods | |
| US11667687B2 (en) | Masked activatable interferon constructs | |
| WO2023060188A1 (en) | Activatable cytokine constructs and combination methods | |
| CN120958015A (zh) | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 | |
| US20240400630A1 (en) | Activatable cytokine constructs and related compositions and methods | |
| WO2024216170A2 (en) | Activatable cytokine constructs and related compositions and methods | |
| WO2024216146A1 (en) | Masking polypeptides, activatable cytokine constructs, and related compositions and methods | |
| EA053125B1 (ru) | Активируемые цитокиновые конструкции и связанные c ними композиции и способы | |
| CN118076628A (zh) | 可活化细胞因子构建体及相关组合物和方法 | |
| CN118043064A (zh) | 可活化细胞因子构建体及组合方法 | |
| WO2026020161A1 (en) | Activatable il-12 constructs and related compositions and methods | |
| CN114634577A (zh) | 融合蛋白及其制备用于治疗肿瘤和病毒感染的药物的应用 |